Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data

References

• FramptonJETafenoquine: first global approvalDrugs201878141517152330229442
   PubMed Web of Science ®Google Scholar
• World Health OrganizationWorld Malaria Report2010 Available from: https://www.who.int/malaria/publications/atoz/9789241564106/en/Accessed October 25, 2018
   Google Scholar
• BassatQVelardeMMuellerIKey knowledge gaps for Plasmodium vivax control and eliminationAm J Trop Med Hyg2016956 Suppl627127430544
   PubMed Web of Science ®Google Scholar
• World Health OrganizationControl and elimination of Plasmodium vivax malaria: a technical brief2017WHO Available from: http://www.who.int/malaria/publications/world-malaria-report-2017/report/en/Accessed June 8, 2018
   Google Scholar
• MuellerIGalinskiMRBairdJKKey gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasiteLancet Infect Dis20099955556619695492
   PubMed Web of Science ®Google Scholar
• PriceRNTjitraEGuerraCAYeungSWhiteNJAnsteyNMVivax malaria: neglected and not benignAm J Trop Med Hyg2007776 Suppl798718165478
   PubMed Web of Science ®Google Scholar
• BairdJKHoffmanSLPrimaquine therapy for malariaClin Infect Dis20043991336134515494911
   PubMed Web of Science ®Google Scholar
• FernandoDRodrigoCRajapakseSPrimaquine in vivax malaria: an update and review on management issuesMalar J201110135122152065
   PubMed Web of Science ®Google Scholar
• HillDRBairdJKPariseMELewisLSRyanETMagillAJPrimaquine: report from CDC expert meeting on malaria chemoprophylaxis IAm J Trop Med Hyg200675340241516968913
   PubMed Web of Science ®Google Scholar
• ChuCSBanconeGMooreKAHaemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimensPLoS Med2017142e100222428170391
   PubMed Web of Science ®Google Scholar
• LeslieTRabMAAhmadzaiHCompliance with 14-day primaquine therapy for radical cure of vivax malaria – a randomized placebo-controlled trial comparing unsupervised with supervised treatmentTrans R Soc Trop Med Hyg200498316817315024927
   PubMed Web of Science ®Google Scholar
• BruecknerRPCosterTWescheDLShmuklarskyMSchusterBGProphylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarialAntimicrob Agents Chemother1998425129312949593172
   PubMed Web of Science ®Google Scholar
• CooperRDMilhousWKRieckmannKHThe efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivaxTrans R Soc Trop Med Hyg19948866916927886774
   PubMed Web of Science ®Google Scholar
• BruecknerRPLasseterKCLinETSchusterBGFirst-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarialAm J Trop Med Hyg19985856456499598455
   PubMed Web of Science ®Google Scholar
• Llanos-CuentasALacerdaMVRueangweerayutRTafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (detective): a multicentre, double-blind, randomised, phase 2B dose-selection studyLancet201438399221049105824360369
   PubMed Web of Science ®Google Scholar
• NasveldPKitchenerSEdsteinMRieckmannKComparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force PersonnelTrans R Soc Trop Med Hyg200296668368412625150
   PubMed Web of Science ®Google Scholar
• LellBFaucherJ-FMissinouMAMalaria chemoprophylaxis with tafenoquine: a randomised studyLancet200035592202041204510885356
   PubMed Web of Science ®Google Scholar
• LearyKJRielMARoyMJA randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteersAm J Trop Med Hyg200981235636219635898
   PubMed Web of Science ®Google Scholar
• ElmesNJNasveldPEKitchenerSJKociskoDAEdsteinMDThe efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the southwest PacificTrans R Soc Trop Med Hyg2008102111095110118541280
   PubMed Web of Science ®Google Scholar
• WalshDSWilairatanaPTangDBRandomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapseClin Infect Dis20043981095110315486831
   PubMed Web of Science ®Google Scholar
• WalshDSLooareesuwanSWilairatanaPRandomized dose-ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in ThailandJ Infect Dis199918041282128710479159
   PubMed Web of Science ®Google Scholar
• FukudaMMKrudsoodSMohamedKA randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malariaPLoS One20171211e018737629121061
   PubMed Web of Science ®Google Scholar
• WalshDSEamsilaCSasipraphaTEfficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malariaJ Infect Dis200419081456146315378438
   PubMed Web of Science ®Google Scholar
• Drug approval package: KRINTAFEL (tafenoquine) Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210795Orig1s000TOC.cfmAccessed December 3, 2018
   Google Scholar
• VuongCXieLHPotterBMDifferential cytochrome P450 2D metabolism alters tafenoquine pharmacokineticsAntimicrob Agents Chemother20155973864386925870069
   PubMed Web of Science ®Google Scholar
• PybusBSMarcsisinSRJinXThe metabolism of primaquine to its active metabolite is dependent on CYP 2D6Malar J201312121223782898
   PubMed Web of Science ®Google Scholar
• BennettJWPybusBSYadavaAPrimaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malariaN Engl J Med2013369141381138224088113
   PubMed Web of Science ®Google Scholar
• IdowuORPegginsJOBrewerTGKelleyCMetabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomesDrug Metab Dispos19952311177720510
   PubMed Web of Science ®Google Scholar
• Vásquez-VivarJAugustoOHydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cyclingJ Biol Chem199226710684868541313024
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IClin Pharmacokinet2009481168972319817501
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• MarcsisinSRSousaJCReichardGATafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compoundsMalar J2014131224386891
   PubMed Web of Science ®Google Scholar
• BernardSNevilleKANguyenATFlockhartDAInterethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implicationsOncologist200611212613516476833
   PubMed Web of Science ®Google Scholar
• St JeanPLXueZCarterNTafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2B detective trialMalar J20161519726888075
   PubMed Web of Science ®Google Scholar
• VennerstromJLNuzumEOMillerRE8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerizationAntimicrob Agents Chemother199943359860210049273
   PubMed Web of Science ®Google Scholar
• RobertABenoit-VicalFDechy-CabaretOMeunierBFrom classical antimalarial drugs to new compounds based on the mechanism of action of artemisininPure Appl Chem200173711731188
   Web of Science ®Google Scholar
• PetersWRobinsonBLMilhousWKThe chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605Ann Trop Med Parasitol19938765475528122915
   PubMed Web of Science ®Google Scholar
• 8242018FDA approves Arakoda for malaria prophylaxis in adults Available from: https://www.healio.com/infectious-disease/emerging-diseases/news/online/%7bb8c1d6f6-0622-4f6d-b592-677f47a75c0b%7d/fda-approves-arakoda-for-malaria-prophylaxis-in-adultsAccessed October 2, 2018
   Google Scholar
• GreenJAPatelAKPatelBRTafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjectsJ Clin Pharmacol2014549995100524700490
   PubMed Web of Science ®Google Scholar
• NasveldPEEdsteinMDReidMRandomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjectsAntimicrob Agents Chemother201054279279819995933
   PubMed Web of Science ®Google Scholar
• WarrasakSEuswasAFukudaMMComparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cureInt Ophthalmol Epub 2018 Sep 29
   Web of Science ®Google Scholar
• ShanksGDOlooAJAlemanGMA new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malariaClin Infect Dis200133121968197411700577
   PubMed Web of Science ®Google Scholar
• EdsteinMDNasveldPEKociskoDAKitchenerSJGattonMLRieckmannKHGender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxisTrans R Soc Trop Med Hyg2007101322623016814823
   PubMed Web of Science ®Google Scholar
• US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria | medicines for malaria venture Available from: https://www.mmv.org/newsroom/press-releases/us-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malariaAccessed August 24, 2018
   Google Scholar
• MillerAKHarrellEYeLPharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjectsBr J Clin Pharmacol201376685886723701202
   PubMed Web of Science ®Google Scholar
• HollanderDAAldaveAJDrug-induced corneal complicationsCurr Opin Ophthalmol200415654154815523201
   PubMedGoogle Scholar
• MarmorMFKellnerULaiTYMellesRBMielerWFAmerican Academy of OphthalmologyRecommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)Ophthalmology201612361386139426992838
   PubMed Web of Science ®Google Scholar
• WatsonJTaylorWRJBanconeGChuCSJittamalaPWhiteNJImplications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malariaPLoS Negl Trop Dis2018124e000644029677199
   PubMed Web of Science ®Google Scholar
• RueangweerayutRBanconeGHarrellEJGreenJAHemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteersAm J Trop Med Hyg201797370271128749773
   PubMed Web of Science ®Google Scholar
• HaleBROwusu-AgyeiSFryauffDJA randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparumClin Infect Dis200336554154912594633
   PubMed Web of Science ®Google Scholar
• Research C for DE and. Drug Approvals and Databases – Drug Trials Snapshots: KRINTAFEL Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ucm615729.htmAccessed October 10, 2018
   Google Scholar
• ThakkarNGreenJAKohGDuparcSTeneroDGoyalNPopulation pharmacokinetics of tafenoquine, a novel antimalarialAntimicrob Agents Chemother20186211 24 10 2018
   Web of Science ®Google Scholar
• EdsteinMDKociskoDABrewerTGWalshDSEamsilaCCharlesBGPopulation pharmacokinetics of the new antimalarial agent tafeno-quine in Thai soldiersBr J Clin Pharmacol200152666367011736877
   PubMed Web of Science ®Google Scholar
• CharlesBGMillerAKNasveldPEReidMGHarrisIEEdsteinMDPopulation pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjectsAntimicrob Agents Chemother20075182709271517517850
   PubMed Web of Science ®Google Scholar
• GreenJAMohamedKGoyalNPharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemetherlumefantrine in healthy adult subjectsAntimicrob Agents Chemother20166012 AAC.01588-16-7332
   Web of Science ®Google Scholar
• TeneroDGreenJAGoyalNExposure-response analyses for Tafenoquine after administration to patients with Plasmodium vivax malariaAntimicrob Agents Chemother201559106188619426248362
   PubMed Web of Science ®Google Scholar
• KitchenerSNasveldPEdsteinMDTafenoquine for the treatment of recurrent Plasmodium vivax malariaAm J Trop Med Hyg200776349449617360873
   PubMed Web of Science ®Google Scholar
• RajapakseSRodrigoCFernandoSDTafenoquine for preventing relapse in people with Plasmodium vivax malariaCochrane Database Syst Rev20154CD010458
   Google Scholar
• BeckHPWampflerRCarterNEstimation of the antirelapse efficacy of tafenoquine, using Plasmodium vivax genotypingJ Infect Dis2016213579479926500351
   PubMed Web of Science ®Google Scholar
• DowGSLiuJLinGSummary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countriesMalar J201514147326610844
   PubMed Web of Science ®Google Scholar
• Novitt-MorenoARansomJDowGSmithBReadLTTooveySTafenoquine for malaria prophylaxis in adults: an integrated safety analysisTravel Med Infect Dis201717192728495354
   PubMed Web of Science ®Google Scholar
• CrockettMKainKCTafenoquine: a promising new antimalarial agentExpert Opin Investig Drugs2007165705715
   PubMed Web of Science ®Google Scholar
• McCarthyJSSmithBLReadLTDowLTA randomized, double-blinded, placebo-controlled study in healthy, non-immune adults to determine the schizonticidal activity of tafenoquine after challenge with Plasmodium falciparum blood stage parasites Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372009. Published June 22, 2018Accessed June 22, 2018
   Google Scholar
• RechtJAshleyEAWhiteNJUse of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countriesPLoS Negl Trop Dis2018124e000623029672516
   PubMed Web of Science ®Google Scholar
• AinoonOAlawiyahAYuYHSemiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partially-deficient femalesSoutheast Asian J Trop Med Public Health200334240541412971572
   PubMedGoogle Scholar
• EspinoFEBibitJASornilloJBTanAvon SeidleinLLeyBComparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the PhilippinesPLoS One2016112e014817226849445
   PubMed Web of Science ®Google Scholar
• BanconeGKalnokyMChuCSThe G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjectsSci Rep201771982228852037
   PubMed Web of Science ®Google Scholar
• PATHThis blood test is the key to curing the most stubborn form of malaria Available from: https://path.org/articles/blood-test-key-curing-most-stubborn-form-malaria/Accessed December 5, 2018
   Google Scholar
• PalSBansilPBanconeGEvaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patientAm J Trop Med Hyg2019100121322130350771
   PubMed Web of Science ®Google Scholar
• LeyBBanconeGvon SeidleinLMethods for the field evaluation of quantitative G6PD diagnostics: a reviewMalar J2017161
   Web of Science ®Google Scholar
• BardajíAMartínez-EspinosaFEArévalo-HerreraMBurden and impact of Plasmodium vivax in pregnancy: a multi-centre prospective observational studyPLoS Negl Trop Dis2017116e000560628604825
   PubMed Web of Science ®Google Scholar
• HeldJJeyarajSKreidenweissAAntimalarial compounds in phase II clinical developmentExpert Opin Investig Drugs2015243363382
   PubMed Web of Science ®Google Scholar
• GuralNMancio-SilvaLMillerABIn vitro culture, drug sensitivity, and transcriptome of Plasmodium vivax hypnozoitesCell Host Microbe201823339540629478773
   PubMed Web of Science ®Google Scholar
• The malERA Refresh Consultative Panel on Basic Science and Enabling TechnologiesmalERA: an updated research agenda for basic science and enabling technologies in malaria elimination and eradicationPLoS Med20171411e100245129190277
   PubMed Web of Science ®Google Scholar
• MarchSNgSVelmuruganSA microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivaxCell Host Microbe201314110411523870318
   PubMed Web of Science ®Google Scholar
• MikolajczakSAVaughanAMKangwanrangsanNPlasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric miceCell Host Microbe201517452653525800544
   PubMed Web of Science ®Google Scholar
• Medicines for Malaria VentureMMV Annual Report 2016Medicines for Malaria Venture Available from: https://www.mmv.org/newsroom/publications/mmv-annual-report-2016. Published June 14, 2018Accessed June 14, 2018
   Google Scholar
• GoyalNMohamedKRolfeKApplication of the stable isotope label approach in clinical development-supporting dissolution specifications for a commercial tablet product with Tafenoquine, a long half-life compoundAAPS J20182047429869298
   PubMed Web of Science ®Google Scholar
• EdsteinMDKociskoDAWalshDSEamsilaCCharlesBGRieckmannKHPlasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxisClin Infect Dis200337121654165814689348
   PubMed Web of Science ®Google Scholar
• DowGSMcCarthyWFReidMSmithBTangDShanksGDA retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic areaMalar J20141314924502679
   PubMed Web of Science ®Google Scholar